{"meshTagsMajor":["Radiotherapy"],"meshTags":["Humans","Cetuximab","Radiotherapy","Antibodies, Monoclonal, Humanized","Keratoacanthoma","Carcinoma, Squamous Cell","Male","Antineoplastic Combined Chemotherapy Protocols","Tongue Neoplasms","Antibodies, Monoclonal","Vocal Cords","Adult","Carcinoma","Pyrimidines","Scalp","Combined Modality Therapy","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Ear Diseases","Thiazoles","Fusion Proteins, bcr-abl","Dasatinib","Neoplasms, Second Primary"],"meshMinor":["Humans","Cetuximab","Antibodies, Monoclonal, Humanized","Keratoacanthoma","Carcinoma, Squamous Cell","Male","Antineoplastic Combined Chemotherapy Protocols","Tongue Neoplasms","Antibodies, Monoclonal","Vocal Cords","Adult","Carcinoma","Pyrimidines","Scalp","Combined Modality Therapy","Leukemia, Myelogenous, Chronic, BCR-ABL Positive","Ear Diseases","Thiazoles","Fusion Proteins, bcr-abl","Dasatinib","Neoplasms, Second Primary"],"genes":["anti-EGFR antibody"],"organisms":["9606"],"publicationTypes":["Case Reports","Journal Article"],"title":"Concomitant and feasible treatment with dasatinib and the anti-EGFR antibody cetuximab plus radiotherapy in a CML patient with multiple squamous neoplasias.","pubmedId":"19842797"}